Caribou Biosciences stock hits 52-week low at $0.95

Caribou Biosciences Inc. (CRBU) stock has tumbled to a 52-week low, touching down at $0.95. This latest price point marks a significant downturn for the biotechnology company, which specializes in CRISPR gene-editing technology. According to InvestingPro data, despite the decline, the company maintains a strong liquidity position with a current ratio of 7.16 and more cash than debt on its balance sheet. Over the past year, Caribou Biosciences has seen its stock value plummet, with a staggering 1-year change of -81.23%. This decline reflects investor concerns and broader market trends that have impacted the biotech sector, leading to a cautious outlook among shareholders and potential investors. Despite the current market sentiment, analysts maintain a bullish consensus on the stock, with price targets ranging from $3 to $34. For deeper insights into CRBU’s valuation and growth prospects, InvestingPro subscribers can access 13 additional key insights and a comprehensive Pro Research Report, part of the platform’s coverage of over 1,400 US stocks.

In other recent news, Caribou Biosciences reported a narrower-than-expected loss for the fourth quarter of 2024. The company posted a Q4 loss of $0.39 per share, outperforming analyst estimates of a $0.42 per share loss. However, revenue for the quarter was $2.08 million, slightly below the consensus estimate of $2.12 million and down from $3.6 million in the same quarter last year. Caribou ended 2024 with $249.4 million in cash, cash equivalents, and marketable securities, which it expects will fund operations into the second half of 2026. The company is advancing four clinical programs for hematologic malignancies and autoimmune diseases, with two key clinical data readouts anticipated in the first half of 2025. For the full year 2024, Caribou reported a net loss of $149.1 million, wider than the $102.1 million loss in 2023, primarily due to increased research and development expenses.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.